Objectives: In 2010,
tamsulosin 0.2 mg (OD) was withdrawn from Thailand and replaced with tamsulosin
0.4 mg (OD). Therefore, we assessed the impact of this change on the patients,
at a men’s health clinic, with lower urinary tract symptoms suggestive of
benign prostatic hyperplasia (LUTS/BPH). Material and Methods: Subjects
were 100 men with BPH who had been taking tamsulosin 0.2 mg as needed for at
least 3 months. The outcome measures were IPSS, AMS and IEFF5 scores and
uroflowmetry. Tolerability was evaluated on by adverse events. Changes from
baseline were assessed using the paired t-test. SPSS version 12.0 was
used for statistical analysis, with p
<0.05 considered significant. Results: The mean followup of
tamsulosin 0.2 and 0.4 mg were 20.23 and 10.56 months respectively. On
switching from tamsulosin 0.2 to 0.4 mg, mean IPSS score improved from 15.54±SD 1.25
to 14.13±SD 1.09 (p=0.034), Q max 15.91 cm3/sec ±SD 1.36 to 16.69 cm3/sec ±SD 1.52
(p=0.128), and nocturia 3.15 ±SD 0.32 to 2.68 ±SD 0.39 (p=0.015),
respectively. However IEFF-5 score and AMS score increased from14.78±SD 1.38
to 15.79
References
[1]
R. Webber, “Benign Prostatic Hyperplasia,” Clinical Evidence, Vol. 15, 2006, pp. 1213-1226.
[2]
S. J. Jacobsen, C. J. Girman, H. A. Guess, et al., “Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling Men,” Journal of Urology, Vol. 155, No. 2, 1996, pp. 595-600.
[3]
M. J. Barry, F. J. Fowler, L. Bin, et al., “The Natural History of Patients with Benign,” 1997.
[4]
P. Narayan and H. S. G. R. Tunuguntla, “Long-Term Efficacy and Safety of Tamsulosin for Benign Prostatic Hyperplasia,” Review in Urology, Vol. 7, 2005, pp. 42-45.
[5]
F. C. Lowe, “Summary of Clinical Experiences with Tamsulosin for the Treatment of Benign Prostatic Hyperplasia,” Review of Urology, Vol. 7, No. 3, 2005, pp. 13-21.
[6]
J.-W. Chung, S. H. Choi, B. S. Kim, T.-H. Kim, E. S. Yoo, C. Il Kim, K. S. Lee and T. G. Kwon, “Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia,” Korean Journal of Urology, Vol. 52, No. 7, 2011, pp. 479-484.
[7]
A. K. Erik, “Storage and Voiding Symptoms: Pathophysiologic Aspects,” Journal of Urology, Vol. 62, No. 3, 2003, pp. 3-10.
[8]
R. Sakakibara, S. Hamano, T. Uchiyama, Z. Liu, T. Yamanishi and T. Hattori, “Do BPH Patients Have Neurogenic Detrusor Dysfunction? A Uro-Neurological Assessment,” Journal of Urology, Vol. 74, No. 1, 2005, pp. 44-50.
[9]
R. Christopher, J. E. Batista, R. Berges, E. Chartier-Kastler, A. Tubaro, P. Van Kerrebroeck and H. Stoevelaar, “The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations,” Journal of European Urology, Vol. 5, Suppl. 5, 2006, pp. 12-18.
[10]
P. Van Kerrebroeck, “Nocturia and Tamsulosin OCAS,” Journal of European Urology, Vol. 6, 2007, pp. 695-760.
[11]
M. H. Braun, F. Sommer, G. Haupt, M. J. Mathers, B. Reifenrath and U. H. Engelmann, “Lower Urinary Tract Symptoms and Erectile Dysfunction: Co-Morbidity or Typical ‘Aging Male’ Symptoms? Results of the ‘Cologne Male Survey’,” European Urology, Vol. 44, No. 5, 2003, pp. 588-594.
[12]
R. Kumar, A. Nehra, D. J. Jacobson, M. E. McGree, N. M. Gades, M. M. Lieber, S. J. Jacobsen and J. L. St. Sauver, “Alpha-Blocker Use Is Associated with Decreased Risk of Sexual Dysfunction,” Journal of Urology, Vol. 74, No. 1, 2009, pp. 82-87.
[13]
S. Permpongkosol, S. Krilad-O-Larn and K. Ratana-OLarn, “Treatment with a Uroselective α1-Blocker Improves Voiding and Sexual Function: A Study in Thai Men with lower Urinary Tract Symptoms,” Journal of Sex Medicine, Vol. 13, No. 4, 2011, pp. 534-536.
